Analytical Data
-
Gene name
BRCA2
- Application
-
Alternative Names
BRCA2；FACD；FANCD1；Breast cancer type 2 susceptibility Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P51587
-
Expression Region
3319-3418aa
-
AA Sequence
SPQMTPFKKFNEISLLESNSIADEELALINTQALLSGSTGEKQFISVSES TRTAPTSSEDYLRLKRRCTTSLIKEQESSQASTEECEKNKQDTITTKKYI
-
Molecular Weight
37 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BRCA2, a crucial gene linked to hereditary breast and ovarian cancer, encodes a protein that plays a vital role in the repair of DNA double-strand breaks through homologous recombination. The importance of BRCA2 in maintaining genomic stability has been underscored by its association with an increased risk of developing cancers when mutated. The BRCA2 protein facilitates the recruitment and stabilization of RAD51, a key enzyme involved in the recombination process, thereby preventing genomic instability and tumorigenesis. Research into BRCA2 has expanded over the years, focusing on its molecular mechanisms, role in DNA repair pathways, and implications in cancer therapies such as PARP inhibitors. Understanding the structure and function of BRCA2 is critical, not only for identifying individuals at risk but also for developing targeted treatments that exploit the vulnerabilities in cancer cells with BRCA2 mutations. Recent advancements in protein interaction studies and structural biology have provided deeper insights into BRCA2’s function and its interplay with other proteins involved in the DNA repair machinery, paving the way for innovative therapeutic strategies aimed at enhancing cancer treatment efficacy and personalizing patient care. The ongoing research surrounding BRCA2 continues to unveil its complexity and significance in cancer biology, reinforcing the need for further exploration of its therapeutic potential and the development of genetic screening methods to improve early detection and intervention for at-risk populations.
